Classification of stomach adenocarcinoma based on fatty acid metabolism-related genes frofiling

被引:5
作者
Liu, Chunhua [1 ]
Tao, Yongjun [1 ]
Lin, Huajian [1 ]
Lou, Xiqiang [1 ]
Wu, Simin [1 ]
Chen, Liping [2 ]
机构
[1] Zhejiang Univ Tradit Chinese Med, Lishui Hosp Tradit Chinese Med, Dept Tumor Rehabil Ctr, Lishui, Peoples R China
[2] Zhejiang Univ Tradit Chinese Med, Lishui Hosp Tradit Chinese Med, Res Ctr, Lishui, Peoples R China
关键词
fatty acid metabolism; stomach adenocarcinoma; tumor immune microenvironment; immune checkpoint inhibitors therapy; prognosis; GASTRIC-CANCER; CELL METABOLISM; STATISTICS; EXPRESSION; REQUIREMENTS; GLYCOLYSIS; PHENOTYPE; PROGNOSIS; HALLMARKS; GROWTH;
D O I
10.3389/fmolb.2022.962435
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Fatty acid metabolism (FAM)-related genes play a key role in the development of stomach adenocarcinoma (STAD). Although immunotherapy has led to a paradigm shift in STAD treatment, the overall response rate of immunotherapy for STAD is low due to heterogeneity of the tumor immune microenvironment (TIME). How FAM-related genes affect TIME in STAD remains unclear. Methods: The univariate Cox regression analysis was performed to screen prognostic FAM-related genes using transcriptomic profiles of the Cancer Genome Atlas (TCGA)-STAD cohort. Next, the consensus clustering analysis was performed to divide the STAD cohort into two groups based on the 13 identified prognostic genes. Then, gene set enrichment analysis (GSEA) was carried out to identify enriched pathways in the two groups. Furthermore, we developed a prognostic signature model based on 7 selected prognostic genes, which was validated to be capable in predicting the overall survival (OS) of STAD patients using the univariate Cox regression, least absolute shrinkage and selection operator (LASSO) regression, and multivariate Cox regression analyses. Finally, the "Estimation of STromal and Immune cells in MAlignant Tumours using Expression data " (ESTIMATE) algorithm was used to evaluate the stromal, immune, and ESTIMATE scores, and tumor purity of each STAD sample. Results: A total of 13 FAM-related genes were identified to be significantly associated with OS in STAD patients. Two molecular subtypes, which we named Group 1 and Group 2, were identified based on these FAM-related prognostic genes using the consensus clustering analysis. We showed that Group 2 was significantly correlated with poor prognosis and displayed higher programmed cell death ligand 1 (PD-L1) expressions and distinct immune cell infiltration patterns. Furthermore, using GSEA, we showed that apoptosis and HCM signaling pathways were significantly enriched in Group 2. We constructed a prognostic signature model using 7 selected FAM-related prognostic genes, which was proven to be effective for prediction of STAD (HR = 1.717, 95% CI = 1.105-1.240, p < 0.001). After classifying the patients into the high- and low-risk groups based on our model, we found that patients in the high-risk group tend to have more advanced T stages and higher tumor grades, as well as higher immune scores. We also found that the risk scores were positively correlated with the infiltration of certain immune cells, including resting dendritic cells (DCs), and M2 macrophages. We also demonstrated that elevated expression of gamma-glutamyltransferase 5 (GGT5) is significantly associated with worse OS and disease-free survival (DFS), more advanced T stage and higher tumor grade, and increased immune cell infiltration, suggesting that STAD patients with high GGT5 expression in the tumor tissues might have a better response to immunotherapy. Conclusion: FAM-related genes play critical roles in STAD prognosis by shaping the TIME. These genes can regulate the infiltration of various immune cells and thus are potential therapeutic targets worthy of further investigation. Furthermore, GGT5 was a promising marker for predicting immunotherapeutic response in STAD patients.
引用
收藏
页数:18
相关论文
共 63 条
  • [11] Long noncoding RNAs and the genetics of cancer
    Cheetham, S. W.
    Gruhl, F.
    Mattick, J. S.
    Dinger, M. E.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 108 (12) : 2419 - 2425
  • [12] Monoamine Oxidase A is a Major Mediator of Mitochondria! Homeostasis and Glycolysis in Gastric Cancer Progression
    Chen, Ling
    Guo, Li
    Sun, Ziwen
    Yang, Guochun
    Guo, Jing
    Chen, Kai
    Xiao, Ruixue
    Yang, Xigui
    Sheng, Lijun
    [J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 8023 - 8035
  • [13] Depression promotes prostate cancer invasion and metastasis via a sympathetic-cAMP-FAK signaling pathway
    Cheng, Yan
    Gao, Xing-Hua
    Li, Xian-Jing
    Cao, Qiu-Hua
    Zhao, Dan-Dan
    Zhou, Jin-Rong
    Wu, Hong-Xi
    Wang, Yun
    You, Lin-Jun
    Yang, Hong-Bao
    He, Yun-Long
    Li, Yong-Ren
    Bian, Jin-Song
    Zhu, Qing-Yi
    Birnbaumer, Lutz
    Yang, Yong
    [J]. ONCOGENE, 2018, 37 (22) : 2953 - 2966
  • [14] A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?
    Ciliberto, Domenico
    Staropoli, Nicoletta
    Caglioti, Francesca
    Gualtieri, Simona
    Fiorillo, Lucia
    Chiellino, Silvia
    De Angelis, Antonina Maria
    Mendicino, Francesco
    Botta, Cirino
    Caraglia, Michele
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    [J]. CANCER BIOLOGY & THERAPY, 2015, 16 (08) : 1148 - 1159
  • [15] Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism
    Dahabieh, Michael S.
    Di Pietro, Erminia
    Jangal, Maika
    Goncalves, Christophe
    Witcher, Michael
    Braverman, Nancy E.
    del Rincon, Sonia V.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2018, 1870 (01): : 103 - 121
  • [16] Brick by brick: metabolism and tumor cell growth
    DeBerardinis, Ralph J.
    Sayed, Nabil
    Ditsworth, Dara
    Thompson, Craig B.
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2008, 18 (01) : 54 - 61
  • [17] Dong Li-hua, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P318
  • [18] Novel immune-risk score of gastric cancer: A molecular prediction model combining the value of immune-risk status and chemosensitivity
    Duan, Shijie
    Wang, Pengliang
    Liu, Funan
    Huang, Hanwei
    An, Wen
    Pan, Siwei
    Wang, Xin
    [J]. CANCER MEDICINE, 2019, 8 (05): : 2675 - 2685
  • [19] Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
    Fuchs, Charles S.
    Doi, Toshihiko
    Jang, Raymond W.
    Muro, Kei
    Satoh, Taroh
    Machado, Manuela
    Sun, Weijing
    Jalal, Shadia I.
    Shah, Manish A.
    Metges, Jean-Phillipe
    Garrido, Marcelo
    Golan, Talia
    Mandala, Mario
    Wainberg, Zev A.
    Catenacci, Daniel V.
    Ohtsu, Atsushi
    Shitara, Kohei
    Geva, Ravit
    Bleeker, Jonathan
    Ko, Andrew H.
    Ku, Geoffrey
    Philip, Philip
    Enzinger, Peter C.
    Bang, Yung-Jue
    Levitan, Diane
    Wang, Jiangdian
    Rosales, Minori
    Dalal, Rita P.
    Yoon, Harry H.
    [J]. JAMA ONCOLOGY, 2018, 4 (05)
  • [20] Guo Deliang, 2013, CNS Oncol, V2, P289